AngioDynamics (ANGO) Updates FY 2019 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.85. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $358.26 million.AngioDynamics also updated its FY19 guidance to $0.82-0.86 EPS.

Shares of ANGO stock traded up $0.44 during mid-day trading on Friday, hitting $20.80. 131,003 shares of the company’s stock were exchanged, compared to its average volume of 235,296. AngioDynamics has a fifty-two week low of $18.11 and a fifty-two week high of $25.48. The company has a quick ratio of 1.70, a current ratio of 2.68 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $762.93 million, a price-to-earnings ratio of 28.11 and a beta of 0.75.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.03). The business had revenue of $86.34 million for the quarter, compared to analyst estimates of $88.30 million. AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. AngioDynamics’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.23 EPS. As a group, analysts anticipate that AngioDynamics will post 0.83 earnings per share for the current fiscal year.

Several brokerages recently weighed in on ANGO. BidaskClub lowered AngioDynamics from a hold rating to a sell rating in a research report on Wednesday. Zacks Investment Research raised AngioDynamics from a sell rating to a hold rating in a research report on Thursday, April 11th. Canaccord Genuity increased their target price on AngioDynamics from $20.00 to $23.00 and gave the stock a hold rating in a research report on Monday, January 7th. TheStreet lowered AngioDynamics from a b rating to a c+ rating in a research report on Thursday, April 18th. Finally, ValuEngine lowered AngioDynamics from a buy rating to a hold rating in a research report on Friday, April 19th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. AngioDynamics presently has a consensus rating of Hold and a consensus price target of $23.50.

TRADEMARK VIOLATION NOTICE: This report was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: Economic Reports

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with's FREE daily email newsletter.